3 Responses

  1. Adam Bryson 28 December 2020 at 10:22 | | Reply

    Thank you for this well researched, balanced and informative piece. Synairgen’s inhaled compound, SNG001, is about to commence a phase 3 clinical trial imminently. This trial will be carried out in many European countries as well as elsewhere across the world. If successful, it would place this compound in a strong position to offer treatment to people suffering a range of viral respiratory infections including COVID-19, particularly those whose intrinsic immune defences are weak whether because of age, chronic cardio-respiratory illness or otherwise. For me, the great asset of the treatment is that, as this article describes, interferons are part of the body’s intrinsic defence system against viral infection and this treatment offers to reinforce those natural defences.

  2. Matt Williamson 28 December 2020 at 10:47 | | Reply

    Excellent article.

    As an asthma sufferer too (albeit mild) in very aware of the issues of viral infections and have been following the progress of Synairgen and SNG001 closely.

    I wish the Government had done more to expedite this treatment during the summer, as it’s been clear to see the number of publications indicating that interferon drugs will be an effective early stage treatment for COVID-19.

    For those of you reading who may be unaware, Synairgen still has the home trial (in the UK) running for elderly, vulnerable people…

  3. Peter 28 December 2020 at 12:11 | | Reply

    I just added your article to my interferon subreddit, where I try to collect information on interferon and COVID-19. Interferon also looks useful as a prophylactic as you can see from the links there.

Leave a Reply